Simulations Plus, Inc. (SLP) stock: key figures, P/E, revenue and dividend
Information Technology · United States · ISIN US8292141053
Simulations Plus, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 79.18 m USD |
| Gross profit | 46.22 m USD |
| Operating income | -70.73 m USD |
| EBIT | -70.10 m USD |
| Net income | -64.72 m USD |
| Diluted EPS – continuing operations | -3.22 USD |
Full history since 1996, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Simulations Plus, Inc.
Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. It operates through Software and Services segments. The company offers GastroPlus, which predicts absorption, biopharmaceutics, pharmacokinetics, and pharmacodynamics in humans and animals; and DDDPlus and MembranePlus simulation products. It also provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, OBESITYsym, and Thales products. In addition, the company offers Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET) predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Further, it provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Additionally, the company offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Research Triangle Park, North Carolina.
More stocks
- Napatech A/S (NAPA.OL)
- Beijing InterAct Technology Co Ltd (300419.SZ)
- QC Solar (Suzhou) Co. Ltd. A (301278.SZ)
- ExaWizards Inc (4259.T)
- Energy Recovery, Inc. (ERII)
- San Fu Chemical Co Ltd (4755.TW)
- UTIMES ORD A (SHH) EQSW Exp: (688638.SS)
- Hollyland China Electronics Technology Corp Ltd (002729.SZ)
- ECS ICT Bhd (5162.KL)
- Rogaland Sparebank (ROGS.OL)
- Focus Minerals Ltd (FML.AX)
- Taiwan Steel Union Co Ltd (6581.TW)
Not investment advice. All data without warranty, price as of 05.10.2026. Details in the risk notice.